ATE120093T1 - Meningococcales klasse i-aussenmembranprotein- vakzin. - Google Patents

Meningococcales klasse i-aussenmembranprotein- vakzin.

Info

Publication number
ATE120093T1
ATE120093T1 AT90901397T AT90901397T ATE120093T1 AT E120093 T1 ATE120093 T1 AT E120093T1 AT 90901397 T AT90901397 T AT 90901397T AT 90901397 T AT90901397 T AT 90901397T AT E120093 T1 ATE120093 T1 AT E120093T1
Authority
AT
Austria
Prior art keywords
class
meningococcales
outer membrane
membrane protein
protein vaccine
Prior art date
Application number
AT90901397T
Other languages
English (en)
Inventor
Robert C Seid Jr
Peter R Paradiso
Jan T Poolman
Peter Hoogerhout
Emmanuel J H J Wiertz
Der Ley Peter Van
John Edward Arun Way W Heckels
Ian Nicholas Fernyhurst Clarke
Original Assignee
Praxis Biolog Inc
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27352237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE120093(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NL8803111A external-priority patent/NL8803111A/nl
Application filed by Praxis Biolog Inc, Nederlanden Staat filed Critical Praxis Biolog Inc
Application granted granted Critical
Publication of ATE120093T1 publication Critical patent/ATE120093T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT90901397T 1988-12-19 1989-12-19 Meningococcales klasse i-aussenmembranprotein- vakzin. ATE120093T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL8803111A NL8803111A (nl) 1988-12-19 1988-12-19 Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
NL8900036A NL8900036A (nl) 1988-12-19 1989-01-06 Multivalent meningococcen klasse 1 buitenmembraaneiwit vaccin.
NL8901612A NL8901612A (nl) 1988-12-19 1989-06-26 Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.

Publications (1)

Publication Number Publication Date
ATE120093T1 true ATE120093T1 (de) 1995-04-15

Family

ID=27352237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90901397T ATE120093T1 (de) 1988-12-19 1989-12-19 Meningococcales klasse i-aussenmembranprotein- vakzin.

Country Status (10)

Country Link
EP (1) EP0449958B9 (de)
JP (1) JP3436756B2 (de)
AT (1) ATE120093T1 (de)
AU (1) AU640118B2 (de)
DE (1) DE68921895T3 (de)
DK (1) DK175788B1 (de)
ES (1) ES2070312T5 (de)
FI (1) FI113009B (de)
NO (1) NO305463B1 (de)
WO (1) WO1990006696A2 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
EP0668778A1 (de) * 1992-10-26 1995-08-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunisierung gegen neisseria gonorrhoeae und neisseria meningitidis
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
BR9609882A (pt) * 1995-08-04 1999-07-27 Univ Guelph Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana
PT854729E (pt) * 1995-09-18 2004-08-31 Us Army Med Res Mat Com Usamrm Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente
EP0909323B1 (de) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bakterioferritin aus helicobacter pylori
GB9611673D0 (en) * 1996-06-05 1996-08-07 Peptide Therapeutics Ltd Meningococcal vaccine
US6048527A (en) * 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9701489D0 (en) * 1997-01-24 1997-03-12 Auspharm Int Ltd Antigen
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
EP1741443B1 (de) * 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Kombinierte Meningitis B/C Impfstoffe
ES2278446T3 (es) * 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
AU2003213540B8 (en) * 1998-05-29 2006-09-28 Novartis Vaccines And Diagnostic Inc. Combination meningitidis B/C vaccines
GB9814902D0 (en) * 1998-07-10 1998-09-09 Univ Nottingham Screening of neisserial vaccine candidates against pathogenic neisseria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US6693186B2 (en) * 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
WO2000042193A1 (en) * 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigen
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
EP1069133A1 (de) 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis Zusammensetzungen und ihre Verwendungen als anti-infektionsmitteln
GB9916529D0 (en) * 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
PT2275551E (pt) * 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ATE460484T1 (de) * 1999-11-29 2010-03-15 Novartis Vaccines & Diagnostic 85 kda antigen von neisseria
DK1112747T3 (da) * 1999-12-28 2004-10-25 Akzo Nobel Nv Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
ES2588917T3 (es) * 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
AU2818101A (en) * 2000-01-25 2001-08-07 University Of Queensland, The proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
MXPA03000822A (es) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
CA2435681C (en) 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
JP2004529643A (ja) 2001-04-17 2004-09-30 カイロン コーポレイション 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP1499712A4 (de) 2002-04-12 2008-04-16 Melbourne Health Hepatitis-b-virusvarianten mit verminderter empfindlichkeit gegenüber nukleosidanalogen und verwendung davon
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2351579B1 (de) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Poylpeptidimpfstoffe zum breiten Schutz gegen hypervirulente Meningo-kokken-Linien
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005042564A1 (en) * 2003-10-20 2005-05-12 Sidney Kimmel Cancer Center Flagellin fusion proteins as adjuvants or vaccines and methods of use
PL1745075T3 (pl) 2004-04-21 2013-09-30 Brigham & Womens Hospital Inc Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
EP1874923A4 (de) 2005-04-08 2010-08-04 Melbourne Health Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon
US8211443B2 (en) 2005-04-08 2012-07-03 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
GB0809659D0 (en) * 2008-05-28 2008-07-02 Univ Nottingham Polypeptides
MX2010012999A (es) 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
CN102159540B (zh) 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
JP2012090571A (ja) * 2010-10-27 2012-05-17 Sekisui Chem Co Ltd 動物の免疫方法、免疫用組成物、抗体の製造方法、並びに、ハイブリドーマの製造方法
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
ES2762481T3 (es) * 2014-04-17 2020-05-25 Corning Inc Recipiente para cultivo celular y su uso
EP3174893B1 (de) * 2014-07-30 2020-05-06 Genome Protection, Inc. Flagellinzusammensetzungen und verwendungen
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
JP2023542141A (ja) * 2020-09-15 2023-10-05 ザ ユニバーシティー オブ モンタナ 繊維状バクテリオファージを標的化する組成物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
WO1983003354A1 (en) * 1982-03-30 1983-10-13 Us Army Neisseria gonorrhoeae vaccine
DE3483957D1 (de) * 1983-11-21 1991-02-21 Wellcome Found Komplexe, verfahren zu ihrer herstellung und dieselben enthaltende formulierungen.
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
DE68922394T2 (de) * 1988-05-05 1995-10-05 Praxis Biolog Inc Rekombinante vakzine von flagellin.

Also Published As

Publication number Publication date
NO305463B1 (no) 1999-06-07
EP0449958B9 (de) 2003-05-28
EP0449958B1 (de) 1995-03-22
DK175788B1 (da) 2005-02-21
DE68921895T3 (de) 2003-05-22
ES2070312T5 (es) 2003-05-16
WO1990006696A2 (en) 1990-06-28
EP0449958B2 (de) 2002-11-13
FI113009B (fi) 2004-02-27
NO912369L (no) 1991-08-06
DE68921895D1 (de) 1995-04-27
AU4821990A (en) 1990-07-10
EP0449958A1 (de) 1991-10-09
NO912369D0 (no) 1991-06-18
ES2070312T3 (es) 1995-06-01
JP3436756B2 (ja) 2003-08-18
DK117491A (da) 1991-08-15
AU640118B2 (en) 1993-08-19
FI912965A0 (fi) 1991-06-18
DK117491D0 (da) 1991-06-18
WO1990006696A3 (en) 1990-07-12
JPH06503465A (ja) 1994-04-21
DE68921895T2 (de) 1995-09-07

Similar Documents

Publication Publication Date Title
DE68921895D1 (de) Meningococcales klasse i-aussenmembranprotein-vakzin.
DK0680512T3 (da) Immunogent meningokok LPS og ydermembranvesikler og vaccine deraf
FI914129A0 (fi) Nukleotidsekvens som kodar foer protein av den yttre membranen av neisseria meningitidis och an- anvaendning av naemnda protein i vaccin.
DK0561907T3 (da) Proteiner med ændrede epitoper og fremgangsmåder til fremstilling deraf
DE68924162D1 (de) Stressproteine und verwendungen dafür.
ES2063965T3 (es) Vacunas para haemophilus influenzae no tipificable.
DK1378245T3 (da) Transferrin-bindende-proteiner fra neisseria gonorrhoeae og neisseria meningitidis. Deres anvendelse i en vaccine
GB2255093A (en) Hiv-1 core protein fragments
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DE69031351D1 (de) Zubereitungen und behandlungen von pneumonia in tieren
DE68915046D1 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
CA2007248A1 (en) Meningococcal class 1 outer-membrane protein vaccine
ES2057008T3 (es) Medicamento.
NO912823D0 (no) Fremgangsmaate for fremstilling av klasse ii-proteinet av neisseria meningitidis samt vaksiner som inneholder dette.
NO912822D0 (no) Fremgangsmaate for fremstilling av klasse ii-proteinet frayttermembranen til neisseria meningitidis.
NO912824L (no) Fremgangsmaate for fremstilling av klasse ii-proteinet frayttermembranen til neisseria meningitidis.
PT1535928E (pt) Composições de vacina compreendendo proteínas omp85 de neisseria gonorrhoeae e neisseria meningitidis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0449958

Country of ref document: EP

EEFA Change of the company name
EELA Cancelled due to lapse of time